Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment of dyslipidaemia with fluvastatin in patients with type 2 diabetes mellitus - Effects on lipids, mental state and fibrinolysis
Autore:
Visseren, FLJ; Bouter, PK; van Loon, BJP; Erkelens, WD;
Indirizzi:
Univ Utrecht Hosp, Dept Internal & Vasc Med, NL-3584 CX Utrecht, Netherlands Univ Utrecht Hosp Utrecht Netherlands NL-3584 CX CX Utrecht, Netherlands Bosch Med Ctr, Dept Internal Med, Den Bosch, Netherlands Bosch Med Ctr Den Bosch Netherlands nternal Med, Den Bosch, Netherlands Sint Lucas Andreas Ziekenhuis, Dept Internal Med, Amsterdam, Netherlands Sint Lucas Andreas Ziekenhuis Amsterdam Netherlands terdam, Netherlands
Titolo Testata:
CLINICAL DRUG INVESTIGATION
fascicolo: 10, volume: 21, anno: 2001,
pagine: 671 - 678
SICI:
1173-2563(2001)21:10<671:TODWFI>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY HEART-DISEASE; PLASMINOGEN-ACTIVATOR INHIBITOR-1; RISK-FACTORS; INSULIN-RESISTANCE; PLASMA-INSULIN; TRIGLYCERIDE CONCENTRATIONS; MYOCARDIAL-INFARCTION; GLUCOSE-TOLERANCE; VASCULAR-DISEASE; ANGINA-PECTORIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
46
Recensione:
Indirizzi per estratti:
Indirizzo: Visseren, FLJ Univ Utrecht Hosp, Dept Internal & Vasc Med, Room F-02-124,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands Univ Utrecht Hosp Room F-02-124,Heidelberglaan 100 Utrecht Netherlands NL-3584 CX
Citazione:
F.L.J. Visseren et al., "Treatment of dyslipidaemia with fluvastatin in patients with type 2 diabetes mellitus - Effects on lipids, mental state and fibrinolysis", CLIN DRUG I, 21(10), 2001, pp. 671-678

Abstract

Objective: To determine the effects of fluvastatin on lipids, mood and fibrinolysis in dyslipidaemic patients with type 2 diabetes mellitus. Design and Setting: Randomised, double-blind, placebo-controlled study in 12 outpatient clinics of general hospitals in The Netherlands evaluating the use of the HMG-CoA reductase inhibitor fluvastatin for dyslipidaemia [low-density lipoprotein (LDL)-cholesterol >4.1 mmol/L] in patients with type 2diabetes mellitus receiving insulin therapy. Effects on lipids, lipoproteins, fibrinolysis and mood were evaluated. Patients: 42 patients with type 2 diabetes mellitus and dyslipidaemia (LDLcholesterol >4.1 mmol/L) were treated with fluvastatin 40mg once daily and 45 patients received placebo for 12 weeks followed by open-label treatment with fluvastatin for 12 weeks. Results: Fluvastatin reduced serum levels of LDL-cholesterol by 25.5% (p <0.05) compared with placebo after 12 weeks of treatment, but did not affect the levels of the fibrinolytic parameters plasminogen activator inhibitor-1 (PAI-1) and tissue-plasminogen activator (t-PA) or the levels of lipoproteins Lp(a) and apolipoprotein (Apo) A I. Fluvastatin also did not change the mental status of patients with type 2 diabetes mellitus as assessed withthe Zung questionnaire, Adverse reactions were equally distributed betweenthe fluvastatin and placebo groups. Conclusions: In conclusion, fluvastatin treatment for dyslipidaemia in patients with type 2 diabetes mellitus on insulin therapy is effective and well tolerated. Fibrinolysis and mood were not affected by this treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 02:16:34